John David O'Neill
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2018First federal award
$9.3MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $9.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Sep 10, 2026 | NIH | SBIR Phase II Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development | $957K | XYLYX BIO, INC. |
| Aug 7, 2026 | NIH | SBIR Phase II Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation | $1.5M | XYLYX BIO, INC. |
| Jul 23, 2026 | NIH | SBIR Phase II Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development | $1.0M | XYLYX BIO, INC. |
| Sep 10, 2025 | NIH | SBIR Phase II Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development | $968K | XYLYX BIO, INC. |
| Sep 5, 2025 | NIH | SBIR Phase II Translational development and clinical evaluation of a bioengineered human lung graft for clinical transplantation | $1.5M | XYLYX BIO, INC. |
| Jun 12, 2025 | NIH | SBIR Phase II Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development | $966K | XYLYX BIO, INC. |
| Aug 23, 2024 | NIH | SBIR Phase II Liver fibrosis cell-based assay platform: integrating patient-derived fibrotic liver ECM with primary stellate cells, Kupffer cells, and hepatocytes to accelerate anti-fibrotic drug development | $370K | XYLYX BIO, INC. |
| Jun 6, 2024 | NIH | SBIR Phase II Multi-organ metastatic breast cancer cell-based assay platform that models organotropic metastases using patient organoids in human tissue-derived ECMs to accelerate anti-metastatic drug development | $296K | XYLYX BIO, INC. |
| Jun 6, 2023 | NIH | SBIR Phase II Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | $109K | XYLYX BIO, INC. |
| Mar 10, 2023 | NIH | SBIR Phase II Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | $961K | XYLYX BIO, INC. |
| Nov 25, 2022 | NIH | SBIR Phase II Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | $70K | XYLYX BIO, INC. |
| Aug 31, 2021 | NIH | SBIR Phase II Lung fibrosis modeling and compound testing platform using fibrotic lung ECM that recreates the fibrotic disease environment to improve predictiveness and accelerate anti-fibrotic drug development | $298K | XYLYX BIO, INC. |
| Feb 11, 2019 | NIH | SBIR Phase I Native cell specific microenvironments for improved cell culture | $55K | XYLYX BIO, INC. |
| Sep 12, 2018 | NIH | SBIR Phase I Fibrotic lung extracellular matrix cell culture substrate to improve predictive in vitro models of pulmonary fibrosis for accelerating drug development towards more effective treatment options | $225K | XYLYX BIO, INC. |
Peer ranks
Federal funding#78
Awards as PI#57
Patents#273
Companies
- XYLYX BIO, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.